Gerresheimer stock gains as Apax deal and analyst views shape outlook

Gerresheimer stock is trading around the upper 20-euro range as investors weigh the planned Apax-led sale of packaging units and a cluster of Neutral ratings with modest downside to the average price target.

Gerresheimer (ISIN DE000A0LD6E6) stock closed at 27.90 EUR on Xetra as of September 2, 2026, marking a 1.90 percent gain for the day and leaving the shares slightly above the average analyst price target of 27.38 EUR according to MarketScreener data.

Apax prepares financing for Gerresheimer asset deal

According to a Bloomberg report published on September 2, 2026, Apax Partners is lining up about EUR 1.0 billion of debt financing to support the acquisition of two businesses from Gerresheimer, including a revolving credit facility and term loans that are expected to be sold to institutional investors later in the year.

The enterprise value for the transaction, which covers the Centor US business and Gerresheimer's global Primary Packaging Plastics operations, was previously reported at roughly EUR 1.5 billion, illustrating that the planned sale could significantly reshape the group's portfolio and balance sheet once completed, especially in light of the financing package described by Bloomberg.

Analyst consensus and valuation signals

MarketScreener's latest analyzer overview dated September 3, 2026 shows that the consensus recommendation for Gerresheimer stands at Hold, with 13 analysts covering the stock and an average price target of 27.38 EUR compared with the most recent closing price of 27.90 EUR on Xetra, implying a modest downside of 1.88 percent from the current level.

The same MarketScreener summary notes that Berenberg has reiterated a Neutral rating on Gerresheimer with a price target of 24 EUR, while JPMorgan maintains an Overweight stance with a target price of 46 EUR, highlighting a wide dispersion in views on the stock's upside potential despite the overall Hold consensus.

Operations focus on pharmaceutical primary packaging

Gerresheimer AG, headquartered in Germany, positions itself as a specialist supplier to the pharmaceutical and healthcare industries, with operations broadly divided into Plastics and Devices as well as Primary Packaging Glass, and around 40 production sites in Europe, North America, South America and Asia based on the company profile summarized by MarketScreener.

The Plastics and Devices segment develops standard and customized drug delivery solutions such as insulin pens, inhalers and prefillable syringes, while the Primary Packaging Glass segment concentrates on glass packaging for medicines and cosmetics, including injection vials, cartridges, perfume flacons and cream jars, which together form the core of Gerresheimer's revenue base and underpin investor interest in the stock.

Gerresheimer stock and Xetra trading context

MarketScreener's Xetra snapshot for Gerresheimer shows the stock closing at 27.90 EUR as of September 2, 2026, after gaining 1.90 percent on that trading day, with the previous close reported at 27.74 EUR, indicating a short-term rise of 0.16 EUR that reflects investors' reaction to recent corporate developments and analyst updates.

For investors following German mid-cap stocks, Gerresheimer trades on Xetra under the ticker GXI and is classified in the medical supplies sector, meaning the shares often feature in broader discussions of healthcare-related names alongside other DACH-region industrials and pharma suppliers.

Gerresheimer stock key data

• Company: Gerresheimer AG
• ISIN: DE000A0LD6E6
• WKN: A0LD6E
• Ticker: GXI
• Trading venue: Xetra
• Price (as of September 2, 2026, 17:35): 27.90 EUR
• Sector / Industry: Medical supplies / healthcare packaging
• Index membership: MDAX